NRXP
NRX Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$74.40M
P/E Ratio
—
EPS
$-1.34
Beta
1.83
52W High
$3.84
52W Low
$1.62
50-Day MA
$1.95
200-Day MA
$2.56
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
1.27
PEG Ratio
—
About NRX Pharmaceuticals Inc
NRx Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company, develops new treatments for the treatment of life-threatening central nervous system disorders and lung diseases. The company is headquartered in Wilmington, Delaware.
Fundamentals
| Revenue (TTM) | $1.23M |
| Gross Profit (TTM) | 720,000 |
| EBITDA | $-16.12M |
| Operating Margin | -467.30% |
| Return on Equity | -683.00% |
| Return on Assets | -121.80% |
| Revenue/Share (TTM) | $0.06 |
| Book Value | $-0.50 |
| Price-to-Book | 2.90 |
| Price-to-Sales (TTM) | 60.74 |
| EV/Revenue | 53.54 |
| EV/EBITDA | -0.15 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $33.07M |
| Float | $24.24M |
| % Insiders | 8.30% |
| % Institutions | 25.16% |
Analyst Ratings
Consensus ($38.00 target)
4
BuyData last updated: 4/9/2026